Valo and KSM partnered to analyse Israel's largest biobank with Opal for preventive care and personalised medicine.

KSM wanted to unlock insights from genetic and medical data. Opal links genetic information with patient medical records from a biobank of over 800,000 de-identified samples, with medical data on 2.5 million members over 30 years. Expected outcomes are disease connections and new patient subpopulations; none are reported yet.

Valo Health is an AI drug discovery company whose Opal platform combines real-world patient data and computation to find targets and small molecules for partners.

This sits in the Data Providers stage of the AI use-case lifecycle: Named examples from the real-world-data, claims and competitive-intelligence providers pharma AI systems are trained on, benchmarked against, or run inside of.